Lamisil Dermgel

Terbinafine, the active ingredient in Lamisil Dermgel, is an allylamine antifungal presented as a gel for topical use. It inhibits fungal growth and is indicated for the treatment of superficial dermatophyte infections such as tinea pedis (athlete’s foot), tinea corporis (ringworm) and tinea cruris (jock itch) in both adults and children.

GNH USA supplies Lamisil Dermgel as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory conformity. Through robust quality‑assurance processes and reliable logistics networks, the company supports timely delivery across regions.

Lamisil Dermgel (terbinafine) is used to treat superficial fungal infections caused by dermatophytes.

Tinea pedis: reduces symptoms and eliminates the causative dermatophyte on the feet. Tinea corporis: clears ring‑shaped skin lesions caused by fungal infection. Tinea cruris: resolves itching and rash in the groin area due to fungal growth.

Common Side Effects: - Itching or mild burning at the application site. - Redness or erythema of the treated skin. - Stinging sensation during or after application. - Dryness or flaking of the skin.

Serious or Rare Side Effects: - Severe allergic reaction (angioedema, anaphylaxis). - Contact dermatitis with extensive rash or swelling. - Systemic effects such as liver enzyme elevation (rare with topical use).

Before using Lamisil Dermgel, consider the following precautions.

Apply to intact skin: avoid broken or inflamed areas to reduce systemic absorption. Avoid ocular contact: keep the product away from eyes. Do not use on extensive body areas without medical advice. Discontinue if severe irritation occurs: seek medical evaluation. Pregnancy and lactation: consult a healthcare professional before use. Store at ambient temperature: keep the gel in the original container, protect from light and moisture.

Lamisil Dermgel may interact with other topical or systemic agents.

Major Interactions (Avoid): - Systemic terbinafine therapy: concurrent use may increase systemic exposure and risk of toxicity. - Other topical antifungal agents containing azoles: may cause additive skin irritation.

Moderate Interactions (Monitor Closely): - Corticosteroid creams: may mask local reactions, monitor skin condition. - Alcohol‑based skin products: may increase dryness, observe for irritation. - Hepatotoxic chemotherapeutic agents: monitor hepatic function if extensive topical use is required.